TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Total liabilities 2016–2025
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) total liabilities at each fiscal year-end, per SEC filings.
$32.8BFY2025 · since FY2016: $58.1B → $32.8B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $32.8B | -2.3% |
| FY2024 | $33.6B | -4.9% |
| FY2023 | $35.4B | -0.2% |
| FY2022 | $35.4B | -2.8% |
| FY2021 | $36.4B | -8.0% |
| FY2020 | $39.6B | -6.7% |
| FY2019 | $42.4B | -5.5% |
| FY2018 | $44.9B | -13.5% |
| FY2017 | $51.9B | -10.7% |
| FY2016 | $58.1B | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More TEVA financial trends
TEVA RevenueTEVA Net incomeTEVA Net marginTEVA Gross profitTEVA Gross marginTEVA Operating incomeTEVA Operating marginTEVA Operating cash flowTEVA Free cash flowTEVA Capital expendituresTEVA Return on equityTEVA Stock buybacksTEVA Dividends paidTEVA Total assetsTEVA Shareholders’ equityTEVA overview →